Myelodysplastic syndromes - azacitidine (TA218)
NICE recommends azacitidine as a possible treatment for some adults with myelodysplastic syndromes, chronic myelomonocytic leukaemia or acute myeloid leukaemia.
Who can have azacitidine?
People who cannot have a stem cell transplant may be able to have azacitidine. Azacitidine is 'licensed' (approved as being safe by the European regulatory agency) for adults with myelodysplastic syndromes, chronic myelomonocytic leukaemia or acute myeloid leukaemia, but only in specific circumstances, for example, depending on the characteristics of the person's blood and bone marrow.
Why has NICE said this?
NICE looks at how well treatments work, and also at how well they work in relation to how much they cost the NHS. NICE applies special considerations to treatments that can extend the lives of people who are nearing the end of their life. NICE recommended azacitidine because the cost is justified by the benefits it provides when the special considerations are applied.
This page was last updated: 18 May 2011
- Web format
- Quick reference guide (PDF)
- Full Guidance (PDF)
- TA218 Azacitidine ar gyfer syndromau myelodysplastig, lewcemia myelomonosytig cronig a lewcemia myeloid acíwt: deall canllawiau NICE (fformat MS Word)
Information for the public
Implementation tools and resources
See this guidance in practice
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.